Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Oct 11;288(41):29494-505.
doi: 10.1074/jbc.M113.471268. Epub 2013 Aug 22.

Inflammatory cytokines induce a unique mineralizing phenotype in mesenchymal stem cells derived from human bone marrow

Affiliations

Inflammatory cytokines induce a unique mineralizing phenotype in mesenchymal stem cells derived from human bone marrow

Elisabeth Ferreira et al. J Biol Chem. .

Abstract

Bone marrow contains mesenchymal stem cells (MSCs) that can differentiate along multiple mesenchymal lineages. In this capacity they are thought to be important in the intrinsic turnover and repair of connective tissues while also serving as a basis for tissue engineering and regenerative medicine. However, little is known of the biological responses of human MSCs to inflammatory conditions. When cultured with IL-1β, marrow-derived MSCs from 8 of 10 human subjects deposited copious hydroxyapatite, in which authenticity was confirmed by Fourier transform infrared spectroscopy. Transmission electron microscopy revealed the production of fine needles of hydroxyapatite in conjunction with matrix vesicles. Alkaline phosphatase activity did not increase in response to inflammatory mediators, but PPi production fell, reflecting lower ectonucleotide pyrophosphatase activity in cells and matrix vesicles. Because PPi is the major physiological inhibitor of mineralization, its decline generated permissive conditions for hydroxyapatite formation. This is in contrast to MSCs treated with dexamethasone, where PPi levels did not fall and mineralization was fuelled by a large and rapid increase in alkaline phosphatase activity. Bone sialoprotein was the only osteoblast marker strongly induced by IL-1β; thus these cells do not become osteoblasts despite depositing abundant mineral. RT-PCR did not detect transcripts indicative of alternative mesenchymal lineages, including chondrocytes, myoblasts, adipocytes, ligament, tendon, or vascular smooth muscle cells. IL-1β phosphorylated multiple MAPKs and activated nuclear factor-κB (NF-κB). Certain inhibitors of MAPK and PI3K, but not NF-κB, prevented mineralization. The findings are of importance to soft tissue mineralization, tissue engineering, and regenerative medicine.

Keywords: Biomineralization; Bone; Cell Differentiation; Inflammation; Interleukin; Tissue Engineering.

PubMed Disclaimer

Figures

FIGURE 1.
FIGURE 1.
In vitro mineralization by hMSCs in response to dexamethasone, IL-1β, or TNF-α and characterization of mineral by Fourier transform infrared spectroscopy. A, alizarin red staining of hMSC monolayers maintained for 21 days in control medium (Controls) and medium supplemented with 100 nm dexamethasone (Dex) or IL-1β (10 ng/ml). B, amount of calcium deposited by hMSCs maintained in medium supplemented with dexamethasone (100 nm), IL-1β (10 ng/ml), or TNF-α (10 ng/ml) for 21 days. C, dose response for the deposition of mineral in response to IL-1β (n = 3). * denotes a significant difference (p < 0.05) compared with controls lacking IL-1β. # denotes a significant difference (p < 0.05) compared with cells treated with 1 ng/ml IL-1β. D, hMSC viability, expressed as adherent cell DNA/well, at days 10 and 21 after incubation in medium supplemented with dexamethasone or IL-1β (n = 3). * denotes a significant difference (p < 0.05) compared with controls. E, hMSC death measured as lactate dehydrogenase (LDH) release in cell supernatants (left panel) and as caspase-3/7 activity in cell lysates (right panel). Dexamethasone- and IL-1β-treated cultures were maintained for 21 days in medium supplemented with either 5 or 10 mm β-glycerophosphate (n = 3). * denotes a significant difference (p < 0.05) compared with controls for a given β-glycerophosphate concentration. F, FTIR spectra of matrix formed by hMSC monolayers maintained in basal differentiation medium (dashed line) or medium supplemented with dexamethasone (dotted line) or IL-1β (solid line). All data were normalized to the Amide I peak to facilitate comparison of mineral content. Both dexamethasone-treated cultures and IL-1β-treated cultures showed peaks in the mineral region (900–1200 cm−1).
FIGURE 2.
FIGURE 2.
Role of ALP in mineral deposition by hMSCs. A, ALP activity 10 days after incubation in control medium and in medium supplemented with dexamethasone (Dex, 100 nm), IL-1β (10 ng/ml), or TNF-α (10 ng/ml) (n = 3). * denotes a significant difference (p < 0.05) compared with controls. B, kinetics of hMSC ALP activity at days 5, 10, 14, 18, and 21 after treatment with dexamethasone or IL-1β. # denotes a significant difference (p < 0.05) compared with controls. C, inhibition of ALP activity of hMSCs by 100 μm levamisole. # denotes a significant difference (p < 0.05) compared with non-levamisole-treated cells. D, inhibition by levamisole of calcium deposition by dexamethasone- and IL-1β-treated hMSCs (n = 3). # denotes a significant difference (p < 0.05) compared with non-levamisole-treated cells. E, omission of β-glycerophosphate from the differentiation medium eliminated dexamethasone and IL-1β-induced mineralization (n = 3). F, effects of increasing concentrations of inorganic phosphate (NaH2PO4) on mineral deposition by hMSCs treated with dexamethasone or IL-1β (n = 3). * denotes a significant difference (p < 0.05) compared with control for each NaH2PO4 concentration. ∞ denotes a significant difference (p < 0.05) between dexamethasone and IL-1β groups for a given NaH2PO4 concentration. @ denotes a significant difference (p < 0.05) between 4 and 5 mm NaH2PO4 for IL-1β-treated cells.
FIGURE 3.
FIGURE 3.
Changes in ENPP1 activity and intracellular PPi content with time of incubation with dexamethasone and IL-1β. ENPP1 activity (A) and PPi (B) were measured in cell lysates at the indicated times (n = 4). * denotes a significant difference (p < 0.05) compared with controls (white bars). # denotes a significant difference (p < 0.05) between dexamethasone (Dex, gray bars) and IL-1β groups (dotted bars). d, day.
FIGURE 4.
FIGURE 4.
Biochemical properties of matrix vesicles. MVs were isolated from hMSC cultures 14 and 21 d after treatment with dexamethasone (gray bars) or IL-1β (dotted bars) (n = 4). A, ENPP1 activity. B, PPi content. C, ALP activity. D, ALP/ENPP1 ratios. * denotes a significant difference (p < 0.05) compared with controls (white bars). # denotes a significant difference (p < 0.05) between dexamethasone (Dex) and IL-1β groups. @ denotes a significant difference (p < 0.05) between 14 and 21-day-old MV lysates for each group tested.
FIGURE 5.
FIGURE 5.
Transmission EM images of hMSCs cultured under different conditions. A, deposition of abundant mineral in region of cell membrane containing membrane-invested vesicles (denoted by white arrows) in IL-1β treated hMSCs. Scale bars, 200 nm. Black arrows show deposits containing fine, needle-shaped crystals typical of hydroxyapatite. B and C, areas of extracellular matrix of IL-1β-treated cultures containing presumptive matrix vesicles containing mineral (arrows). Scale bars, 500 and 50 nm, respectively. D, needle-shaped crystals of hydroxyapatite were abundant in areas of extracellular matrix of IL-1β-treated cultures. Scale bar, 50 nm.
FIGURE 6.
FIGURE 6.
Cell phenotyping by expression of lineage-related transcripts associated with osteoblast, ligament/tendon, chondrocyte, myoblast, vascular smooth muscle cells, and adipocyte. A, mRNA expression of bone-related marker genes. Real time PCR was used to measure the relative expression of early bone-related marker genes including ALP, osterix, and Runx2 (top panels) as well as late bone-related marker genes including col1A1 (Col I), osteocalcin (OC), osteopontin (OPN), and bone sialoprotein (BSP) (bottom row) in cultures treated with dexamethasone or IL-1β (n = 3). B, mRNA expression of ligament/tendon-related marker, scleraxis (SCXB), cartilage-related marker, aggrecan (ACAN), vascular smooth muscle cell-related marker genes including α-smooth muscle actin (α-SMA) and calponin (SPECC1), and fat-related marker, peroxisome proliferator-activated receptor γ (PPARγ) in cultures treated with dexamethasone or IL-1β (n = 3). mRNA expression levels were normalized to those of the internal standard 18 S rRNA and are reported as relative values (ΔΔCT) to those obtained from the control cell cultures. * denotes a significant difference (p < 0.05) compared with controls.
FIGURE 7.
FIGURE 7.
Signal transduction mechanisms involved in IL-1β-mediated mineralization by hMSCs. A, calcium deposition by hMSCs transduced with increasing doses of recombinant adenovirus (Ad.) carrying the super-repressor form of the inhibitor of κB (srIκB) and exposed to IL-1β for 21 days (left panel) and NF-κB inhibition in hMSC cultures transduced with increased doses of Ad.srIκB and treated with IL-1β for 7 days (right panel) (n = 3). * denotes a significant difference (p < 0.05) compared with cells non-transduced cells. B, assay of MAPK phosphorylation (p38, ERK, and JNK) and Akt phosphorylation by IL-1β was carried out by Western blot analysis. The blots shown are representative of those obtained in one of 4 experiments (n = 4 donors), which each gave similar results. C, effect of JNK, ERK, p38, and PI3K inhibitors and their inactive analogs on IL-1β-induced calcium deposition by hMSCs (n = 3). Inhibitor molecules were not toxic at the concentrations used. # denotes a significant difference (p < 0.05) compared with IL-1β treated cells that were not exposed to inhibitors.

Similar articles

Cited by

References

    1. Caplan A. I., Dennis J. E. (2006) Mesenchymal stem cells as trophic mediators. J. Cell. Biochem. 98, 1076–1084 - PubMed
    1. Arthur A., Zannettino A., Gronthos S. (2009) The therapeutic applications of multipotential mesenchymal/stromal stem cells in skeletal tissue repair. J. Cell. Physiol. 218, 237–245 - PubMed
    1. Pape H. C., Marcucio R., Humphrey C., Colnot C., Knobe M., Harvey E. J. (2010) Trauma-induced inflammation and fracture healing. J. Orthop. Trauma 24, 522–525 - PubMed
    1. Bastian O., Pillay J., Alblas J., Leenen L., Koenderman L., Blokhuis T. (2011) Systemic inflammation and fracture healing. J. Leukoc. Biol. 89, 669–673 - PubMed
    1. Ni Choileain N., Redmond H. P. (2006) Cell response to surgery. Arch. Surg. 141, 1132–1140 - PubMed

Publication types

MeSH terms

LinkOut - more resources